First, FOXO1 was found to be mutated to a presumably activated form in 8.6% of DLBCL (Diffuse large non-B-cell lymphoma); the FOXO1 mutations in this setting were strikingly associated with poor prognosis74. Here, FOXO1 is linked to diffuse large B-cell lymphoma.